|
1. BIOLOGIE
|
|
|
|
2.11 ETIOLOGIE - ALIMENTATION
|
|
|
|
2.13 ETIOLOGIE - NDMA
|
|
|
|
2.6 ETIOLOGIE - ENVIRONNEMENT
|
|
|
|
3.1 PRÉVENTION - TABAC
|
|
|
|
|
3.1.1 PRÉVENTION - TABAC - E-CIGS
|
|
|
|
|
4. DÉPISTAGE, DIAGNOSTIC ET PRONOSTIC
|
|
|
|
4.2 DÉP., DIAG. & PRONO. - GÉNOME
|
|
|
|
|
|
4.3 DÉP., DIAG. & PRONO. - INDUSTRIELS
|
|
|
FTC Slams Illumina-PacBio Merger, but Illumina Not Quitting Yet [Omics! Omics]
|
|
|
|
|
|
Perhaps more important is to identify clinical opportunities that could be generated rapidly and get them into proper trials. Given the high capital cost of an instrument, that's probably going to mean things like oncology or rare diseases (as noted before) where patients can be concentrated at relatively few academic centers. For oncology, it's probably fusion proteins; for rare diseases it's going to be repeat expansion disorders.
|
|
|
|
|
|
|
5. TRAITEMENTS
|
|
|
|
Antioxidant Use During Chemo Risky [SWOG]
|
|
|
|
|
|
Breast cancer patients who take the dietary supplements known as antioxidants, as well as iron, vitamin B12, and omega-3 fatty acids, during chemotherapy may be at increased risk of disease recurrence and death, according to new study results appearing in the Journal of Clinical Oncology.
|
|
|
|
|
|
|
5.1 TRAITEMENTS - PRÉ-CLINIQUE
|
|
|
|
5.12.1 IMMUNOTHÉRAPIES - PARTENARIATS
|
|
|
|
|
|
|
5.12.2 IMMUNOTHÉRAPIES - CAR-T, THÉRAPIES CELLULAIRES
|
|
|
|
5.12.3 IMMUNOTHÉRAPIES-COMBINAISONS
|
|
|
|
5.2 PHARMA
|
|
|
|
|
5.2.3 PHARMA - ÉCONOMIE
|
|
|
|
5.2.6 PHARMA - BIOTECH
|
|
|
|
|
5.3 TRAITEMENTS - FDA, EMA, NICE...
|
|
|
FDA Drafts Guidance on Demonstrating Substantial Evidence of Effectiveness [RAPS]
|
|
|
|
|
|
In addition to the “gold standard” randomized, double-blinded, controlled superiority trials, which FDA says are “regarded as the most rigorous design,” the guidance also discusses other types of designs, including placebo concurrent control, dose-comparison concurrent control, no treatment concurrent control, active treatment concurrent control and historical control designs.
|
|
|
|
|
|
|
6.1 OBSERVATION
|
|
|
|
|
6.10.1 POLITIQUES (USA)
|
|
|
|
6.7 DMP, BIG DATA & APPLIS
|
|
|
|
6.7.1 IA/BIOINFORMATIQUE
|
|
|